Director John Woodson Rollins details AIDX equity stakes at 20/20 Biolabs (AIDX)

Rhea-AI Filing Summary

20/20 Biolabs, Inc. director John Woodson Rollins filed an initial ownership report showing direct holdings of several equity instruments in AIDX. He reports 13,029 shares of Series A Preferred Stock and 6,135 shares of Series A-2 Preferred Stock, each convertible into common stock on a one-for-one basis at his option and automatically if the common stock lists on a national exchange. He also holds multiple stock options, including grants for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares of common stock, with vesting terms described in the notes, and 11,111 shares of common stock directly owned. The filing records existing positions rather than new purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rollins John Woodson

(Last) (First) (Middle)

C/O 20/20 BIOLABS, INC.

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG MD 20877

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/17/2026

3. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,111	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock(1)	(1)	(1)	Common Stock	13,029	(1)	D
Series A-2 Preferred Stock(2)	(2)	(2)	Common Stock	6,135	(2)	D
Stock Option(3)	08/01/2019	07/31/2029	Common Stock	48,780	$0.82	D
Stock Option(4)	01/28/2021	01/27/2031	Common Stock	76,628	$1.044	D
Stock Option(5)	(5)	02/01/2032	Common Stock	37,584	$1.0643	D
Stock Option(6)	02/01/2022	02/01/2032	Common Stock	37,583	$1.0643	D
Stock Option(7)	(7)	01/01/2033	Common Stock	30,000	$1.74	D
Stock Option(8)	(8)	07/01/2034	Common Stock	30,000	$2.55	D

Explanation of Responses:

1. Each share of series A preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A preferred stock has no expiration date.

2. Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.

3. On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.

4. On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.

5. On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.

6. On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.

7. On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

8. On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

	/s/ John W. Rollins	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity holdings does AIDX director John Woodson Rollins report on this Form 3?

John Woodson Rollins reports direct holdings of preferred stock, stock options and common shares. He lists 13,029 Series A Preferred, 6,135 Series A-2 Preferred, several stock option grants, and 11,111 shares of common stock in 20/20 Biolabs, Inc. (AIDX).

How are AIDX Series A and Series A-2 Preferred Stock held by John Woodson Rollins convertible?

Each share of AIDX Series A and Series A-2 Preferred is convertible one-for-one into common stock. Conversion can occur at Rollins’ option at any time, and all outstanding shares convert automatically if AIDX common stock is listed on a national stock exchange.

What stock option grants in AIDX common stock does John Woodson Rollins disclose?

Rollins discloses multiple AIDX stock option grants with specific grant dates and amounts. These include options for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares, with vesting either fully on grant or in equal monthly installments over 12 months.

Does the AIDX Form 3 for John Woodson Rollins show any recent share purchases or sales?

The Form 3 reflects existing holdings, not recent purchases or sales. All transactions are coded as holdings with unknown transaction codes, indicating this filing establishes Rollins’ ownership positions as a director of 20/20 Biolabs, Inc. (AIDX).

What direct common stock ownership in AIDX does John Woodson Rollins report?

Rollins reports direct ownership of 11,111 shares of AIDX common stock. This position is listed separately from his preferred stock and stock option holdings, providing a clear view of his current direct common equity stake in 20/20 Biolabs, Inc.